Introduction {#s01}
============

Pathological retinal angiogenesis is a leading cause of vision loss. The photoreceptor layer is a privileged zone devoid of vasculature to allow light to access photosensitive receptors. Photoreceptors lie between the highly organized but open lattice of vessels in the inner retina, which allows light through to photoreceptors, and the dense sinusoidal vascular plexus, the choriocapillaris, which lies beneath the retinal pigment epithelium (RPE). Both vascular beds are sources of neovascularization extending into the normally avascular photoreceptor and subretinal space between the RPE and the photoreceptor outer segments. The mechanisms by which photoreceptors maintain their avascular state are not well understood, but they are key to understanding neovascular eye diseases, including neovascular age-related macular degeneration (AMD) and macular telangiectasia ([@bib29]). Abnormal blood vessels that extend into this privileged zone not only block light, but also disrupt retinal function to cause blindness ([@bib34]).

Invasion of vessels into photoreceptors has been associated generally with increased inflammatory signals ([@bib19]; [@bib50]), but the timing and the localization of these signals are not well understood, particularly with respect to the initiation signals for neovascularization. Adaptive immunity and inflammation are highly controlled in the photoreceptor/subretinal space ([@bib54]; [@bib36]), maintained by expression of immunosuppressive factors and characterized by lack of immune cells and, thereby, tolerance of foreign antigens ([@bib53]; [@bib36]). Macrophages and dendritic cells are normally absent in the outer retina and are limited to the underlying choroidal vessels.

Eye diseases with pathological angiogenesis have a slow parainflammatory response ([@bib39]; [@bib44]), with changes in adaptive immunity and macrophage infiltration violating the normal ocular environment of immune privilege. In AMD, the blood--retinal barrier breaks down, and immune/inflammatory cells are recruited from the systemic circulation through the choroid or retinal vessels ([@bib3]) and accumulate in the subretinal space. Here, under stress conditions, they eliminate visual byproducts ([@bib67]). In degenerative diseases, this breakdown in the immune privilege may be a compensatory response to maintain vision because impaired microglial migration into or out of the subretinal space promotes photoreceptor cell death ([@bib14]; [@bib11]). Loss of immune privilege may correlate with and increase neovascularization ([@bib6]; [@bib49]). We hypothesized that inflammatory signals from photoreceptors initiate the process to break down their avascular privilege, with secondary alterations in aspects of immune privilege. This mechanism might suggest novel molecular targets for anti-neovascular therapies directed at the initiation step.

The very low-density lipoprotein receptor--deficient (*Vldlr^−/−^*) mouse is a model of pathological angiogenesis invading the avascular zone ([@bib24]; [@bib33]; [@bib12]; [@bib17]; [@bib27]). *Vldlr^−/−^* mice first develop retinal vascular lesions, invading photoreceptors from the retinal vessels, and then later develop choroidal neovascularization (also invading photoreceptors but from the choroidal vessels), associated with cone degeneration and then rod loss ([@bib12]; [@bib17]), retinal vascular leakage, and chronic inflammation, features similar to human neovascular AMD. Previous studies report that dysregulated photoreceptor energy metabolism ([@bib27]) and oxidative stress ([@bib17]) contribute in part to increased levels of vascular endothelial growth factor A (VEGFA), which leads to neovascularization in *Vldlr^−/−^* retinas. Here, we used *Vldlr^−/−^* mice to explore the contribution of photoreceptor-specific inflammatory signals through c-Fos to control photoreceptor vascular privilege.

We postulated that c-Fos, a transcription factor that regulates many inflammatory signals, might control photoreceptor inflammation ([@bib25]). *c-fos* encodes a nuclear DNA-binding phosphoprotein that forms heterodimeric complexes with members of the Jun family of proteins to constitute transcription factor complex activator protein 1 (AP-1; [@bib15]; [@bib22]). AP-1 regulates genes that affect the epidermal microenvironment, including cytokines such as IL-6, TNFα, and matrix proteins ([@bib62]). *c-fos* is one of the immediate early genes ([@bib25]) that are activated transiently and rapidly in response to a wide variety of cellular stimuli. c-Fos promotes inflammation and disease development in inflammatory diseases such as arthritis ([@bib1]; [@bib51]), although it also acts as a negative regulator of inflammatory responses in myeloid and lymphoid cell lineages ([@bib47]).

We found that photoreceptor c-Fos controlled vascular invasion into the photoreceptor layer in *Vldlr^−/−^* mice. Increased c-Fos in *Vldlr^−/−^* photoreceptors was associated with increased expression of its target genes including *Il6* and *Tnf*, which led to activation of the STAT3/VEGFA pathway driven by both IL-6 and TNF/TNFα-induced protein 3 (TNFAIP3)/suppressor of cytokine signaling 3 (SOCS3) signals. Inhibition of c-Fos in photoreceptors using AAV (adeno-associated virus)-*hRK* (human rhodopsin kinase)--*sh_c-fos* blocked neovascularization in *Vldlr^−/−^* mice and rescued visual function. A chemical inhibitor of c-Fos also reduced neovascularization in *Vldlr^−/−^* mice. These findings suggested that photoreceptor c-Fos controls neovascularization through the neuronal STAT3/VEGFA pathway.

In summary, in the *Vldlr^−/−^* retina, in which vessels invade the avascular photoreceptor layer, c-Fos induced inflammatory signals in photoreceptors, leading to increased VEGF, which promoted neovascularization. Macrophage infiltration into the subretinal space occurred only in the late stage. c-Fos is hence a key factor that controls photoreceptor/subretinal space avascular and immune privilege and may be targeted to treat an initiating process in neovascular eye diseases.

Results {#s02}
=======

In the photoreceptor layer of *Vldlr^−/−^* retina, inflammation is seen in association with neovascularization {#s03}
--------------------------------------------------------------------------------------------------------------

There are three retinal vascular layers (superficial, intermediate, and deep) in the normal mouse retina ([Fig. 1 A](#fig1){ref-type="fig"}, left). In the *Vldlr^−/−^* retina, neovascularization extends from the retinal vasculature into the normally avascular photoreceptor layer by postnatal day 12 (P12) and reaches the RPE by P16 ([Fig. 1 A](#fig1){ref-type="fig"}). Newly formed vessels in adult *Vldlr^−/−^* retinas were leaky, as shown with fundus fluorescein angiography (FFA) at P30 ([Fig. 1 B](#fig1){ref-type="fig"}). These ectopic vessels reached the RPE and merged with the choroidal vessels to form retinal--choroidal anastomoses and choroidal neovascularization at ∼6--8 wk of age, violating the avascular privilege of the photoreceptor layer ([Fig. 1 C](#fig1){ref-type="fig"}). Later, in 3-mo-old adult (P90) *Vldlr^−/−^* retinas, IBA1-positive activated macrophages were seen infiltrating into the photoreceptor layer and subretinal space, indicating secondary loss of immune privilege ([Fig. 1 D](#fig1){ref-type="fig"}).

![**c-Fos was induced in *Vldlr^−/−^* retinas.** (A) *Vldlr* deficiency led to neovascularization in the normally avascular photoreceptor layer shown by 3D reconstruction of representative confocal images. *n* = 6. (B) *Vldlr* deficiency led to retinal vascular leakage at 2, 5, and 8 min after intraperitoneal injection of fluorescent dye, as shown by FFA images from P30 WT and *Vldlr^−/−^* mice. *n* = 6. (C) H&E staining showed retinal layer disorganization and retinal-choroidal vascular anastomoses in P60 *Vldlr^−/−^* retinas. Black arrowheads indicate neovascularization. *n* = 6. (D) Macrophage marker IBA1 (green) costained with the endothelial cell marker isolectin (red) and nuclear marker DAPI (blue) in 3-mo *Vldlr^−/−^* retinas with retinal-choroidal vascular anastomoses (arrowhead); macrophages were seen in the subretinal space between the ONL and RPE (arrows). (E) Cytokine expression, including *Il6*, *Il1β*, and *Tnf*, was increased during development in *Vldlr^−/−^* retinas. *n* = 6. (F--L) *c-fos* mRNA and protein expression were markedly increased (F and G) in *Vldlr^−/−^* retinas during development (F), mainly in the P12 ONL (K) and colocalized with the expression of *Vldlr* in P12 WT (H--K) and its target genes including *Il6* and *Tnf* (L). *n* = 6. (H) IHC staining showed increased c-Fos expression in the ONL of P12 *Vldlr^−/−^* retinas. INL, inner nuclear layer; IPL, inner plexiform layer; IS, photoreceptor inner segment; OPL, outer plexiform layer; OS, photoreceptor outer segment; PL, photoreceptor layer; RCA, retinal-choroidal anastomosis; RGC, retinal ganglion cell; WB, Western blot. Bars: (A, 3D) 100 µm; (A, RPE) 250 µm; (C, D, and H) 50 µm; (H, inset) 25 µm. All data are representative of at least three independent experiments. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. Results are presented as mean ± SEM.](JEM_20161645_Fig1){#fig1}

Elevated aqueous inflammatory cytokine levels are found in neovascular AMD patients ([@bib48]). We examined inflammatory cytokine expression in WT and *Vldlr^−/−^* retinas at P12 as vessels began to invade photoreceptors. Total retinal mRNA of inflammatory cytokines *Il6*, *Tnf*, and *Il1β* were markedly increased at P12 in *Vldlr^−/−^* versus WT retinas ([Fig. 1 E](#fig1){ref-type="fig"}). Yet, at this point, there were no detectable macrophages (a potential source of inflammatory cytokines) recruited into the photoreceptor layer and subretinal space (Fig. S1, A--C), as seen in P90 adult retinas ([Fig. 1 D](#fig1){ref-type="fig"}). At P12, there was no difference in the level of mRNA expression of macrophage markers including *Cd45*, *Cd11b*, *Cd68*, and *Cx3cr1* between *Vldlr^−/−^* and WT retinas (Fig. S1 D). These data suggested that *Vldlr* deficiency increased expression of inflammatory cytokines early (≤P12), before macrophage recruitment to the deep layer and the subretinal space, which was seen only at a later stage (3 mo). These results indicated that in *Vldlr^−/−^* retinas, neuronal cell inflammatory signals might initiate neovascularization, followed later by macrophage/immune cell recruitment (Fig. S1), which is consistent with our previous finding that there is no evidence for macrophage-induced onset of neovascularization ([@bib27]).

c-Fos was highly induced in *Vldlr^−/−^* retinas and *si_c-fos* reduced subretinal neovascularization {#s04}
-----------------------------------------------------------------------------------------------------

We examined inflammation as a possible mechanism underlying neovascularization (loss of immune/vascular privilege) in the photoreceptor layer in *Vldlr^−/−^* mice with microarray analyses. *c-fos* expression was markedly increased in P14 *Vldlr^−/−^* versus WT retinas (Table S1). We confirmed an increase in *c-fos* mRNA and protein levels in *Vldlr^−/−^* retinas before and during the development of pathological neovascularization ([Fig. 1, F and G](#fig1){ref-type="fig"}) with c-Fos immunohistochemistry staining ([Fig. 1 H](#fig1){ref-type="fig"}). c-Fos was highly induced in the outer nuclear layer (ONL; photoreceptors) in P12 *Vldlr^−/−^* retinas. To quantitatively localize *c-fos*, we developed a technique to tangentially section whole-mounted retinas and quantify mRNA in 12 individual cellular layers, from retinal ganglion cells to RPE ([Fig. 1, I--L](#fig1){ref-type="fig"}; and Fig. S2). The specificity and homogeneity of sectioned layers was confirmed by quantifying mRNA expression of *rhodopsin* (photoreceptor marker) and platelet endothelial cell adhesion molecule (*Pecam*; vascular endothelial cell marker) in each layer ([Fig. 1 J](#fig1){ref-type="fig"}). Increased *c-fos* expression was mainly seen in the *rhodopsin*-expressing layers where *Vldlr* was also highly expressed ([Fig. 1 K](#fig1){ref-type="fig"}). *c-fos* expression was also increased in layer 2, which mainly contained superficial vessels and retinal ganglion cells, suggesting that *c-fos* may also play a role in cells other than photoreceptors, which needs further study. Target inflammatory genes of *c-fos*, *Il6*, and *Tnf* were identified mainly in the same layer as *Vldlr* and *c-fos*, suggesting that VLDLR/c-Fos might mediate the disruption of angiostatic privilege in the retinal photoreceptor layer by controlling local photoreceptor inflammatory signals ([Fig. 1 L](#fig1){ref-type="fig"}). In addition, the expressions of *Il6* and especially *Tnf* were also increased in layers 8 and 9, which contain the deep layer of retinal vessels. This increase might arise from proliferating endothelial cells, as the deep layer of vessels form at that time.

To suppress increased *c-fos* expression, we used pooled *si_c-fos* comprising three siRNA sequences. The knockdown efficiency was confirmed to be ∼65% in photoreceptor 661W cells (Fig. S3 A). Subretinal injection of the *si_c-fos* pool suppressed both mRNA and protein expression of *c-fos* in the P12 *Vldlr^−/−^* photoreceptor layer by ∼40--50% (Fig. S3, B and C), associated with a reduction in neovascularization in the photoreceptor layer (Fig. S3 D). Three-dimensional (3D) reconstruction of representative confocal images of retinal whole mounts stained with the endothelial cell marker isolectin IB~4~ showed 45% fewer vascular lesions reaching the RPE, which lies beneath the photoreceptors (Fig. S3, D and E). The mean lesion size was also reduced (Fig. S3 F). Thus, knockdown of *c-fos* inhibited neovascularization in *Vldlr^−/−^* retinas.

AAV expressing *sh_c-fos* in the photoreceptor layer inhibited neovascularization and preserved retinal function {#s05}
----------------------------------------------------------------------------------------------------------------

Because of nonspecific targeting and the transient effect of siRNA, *si_c-fos* could neither specifically nor efficiently target photoreceptor cells (Fig. S3). Therefore, we generated a photoreceptor-specific AAV2 carrying shRNA of *c-fos* with the *hRK* promoter ([Fig. 2 A](#fig2){ref-type="fig"}; [@bib28]). Three shRNA sequences were cloned, and the knockdown efficiency was validated using photoreceptor 661W cells (Fig. S3 G). We injected AAV2-*hRK*--*sh_c-fos* subretinally at P1 and evaluated retinas at P16 ([Fig. 2 B](#fig2){ref-type="fig"}). The infection was confirmed with anti-GFP antibody staining in the photoreceptor layer and subretinal space ([Fig. 2 C](#fig2){ref-type="fig"}), showing that 75--80% of the retina was successfully transfected with AAV ([Fig. 2 C](#fig2){ref-type="fig"}). Consequently, both mRNA and protein expression of *c-fos* were reduced by ∼60% ([Fig. 2, D and E](#fig2){ref-type="fig"}), and neovascularization was reduced by \>70% at P16 ([Fig. 2, F and G](#fig2){ref-type="fig"}), as measurements included total retinal areas, which may not be completely affected by AAV2-*hRK*--*sh_c-fos* (∼25% not transfected) as shown ([Fig. 2, C and F](#fig2){ref-type="fig"}, white arrowhead). The mean lesion size was reduced by 83% ([Fig. 2, F--H](#fig2){ref-type="fig"}). AAV2-*hRK*--*sh_c-fos* treatment also prevented vessel leakage ([Fig. 2 I](#fig2){ref-type="fig"}). These results suggest that c-Fos and VLDLR functioned synergistically in maintaining photoreceptor avascular privilege. Moreover, AAV2-*hRK*--*sh_c-fos* significantly rescued visual dysfunction in *Vldlr^−/−^* mice. Untreated *Vldlr^−/−^* mice were characterized by lower electroretinographic photoreceptor sensitivity (a-waves) than age-matched WT mice. AAV2-*hRK*--*sh_c-fos* injection improved photoreceptor sensitivity at 3 mo after injection compared with AAV2-*hRK*--*sh_control*--injected *Vldlr^−/−^* mice ([Fig. 2 J](#fig2){ref-type="fig"}), indicating protection of photoreceptor function.

![**Attenuation of c-Fos in the photoreceptor layer extending to the subretinal space reduced neovascularization.** (A) Schematic diagram illustrating AAV2 carrying *sh_c-fos* within a mir30 cassette under the control of an *hRK* promoter (*hRK-sh_c-fos*). sh_con, sh_control. (B) Time line for AAV subretinal injection and retina collection. (C) The infection of AAV2 in the subretinal space (SS) and photoreceptor layer was confirmed by AAV2-*hRK*-*eGFP*. *n* = 6. INL, inner nuclear layer; RGC, retinal ganglion cell. The white arrowhead indicates the retinal areas were not affected by AAV2-*hRK*-*eGFP* because of the limitation of subretinal injection. (D and E) The knockdown efficiency of *AAV2*-*hRK*--*sh_c-fos* via subretinal injection into *Vldlr^−/−^* retinas was confirmed by comparison with AAV2-*hRK*-*sh_control*--injected retinas at both mRNA (D) and protein (E) levels. (D) \*, P \< 0.05. *n* = 6. (E) \*\*\*, P \< 0.001. *n* = 4. WB, Western blot. (F) Knocking down *c-fos* in the photoreceptor layer (PL) extending to the subretinal space using *AAV2*-*hRK*--*sh_c-fos*--inhibited neovascularization shown by whole-mounted images of AAV2-*hRK*-*sh_control*-- or *AAV2*-*hRK*--*sh_c-fos*--treated *Vldlr^−/−^* retinas stained with isolectin IB4 to label endothelial cells and representative 3D reconstruction images for neovascularization in photoreceptor layers, including the retinal areas, which may not be completely affected by AAV2-*hRK*--*sh_c-fos* (about 25% not transfected) as shown in C (white arrowhead in C and F). (G and H) Both total lesion number and total lesion size (pixels) were reduced in *AAV*-*hRK*--*sh_c-fos*--treated compared with AAV2-*hRK*-*sh_control*--treated retinas. \*\*\*, P \< 0.001. *n* = 8--13. (I) *AAV2*-*hRK*--*sh_c-fos* injected in the subretinal space at P1 rescued *Vldlr* deficiency--induced retinal vascular leakage shown by FFA images at P60 in *Vldlr^−/−^*-treated mice. *n* = 6--8. (J) Representative dark-adapted (scotopic) ERG graph (left) and quantification of photoreceptor a-wave sensitivity (right) showed that photoreceptor function was attenuated in 3-mo-old *Vldlr^−/−^* retinas and was particularly rescued by *AAV*-*hRK*--*sh_c-fos* (one-time treatment on P1) in 3-mo-old *Vldlr^−/−^* retinas. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. Bars: (C and F, whole-mount images) 1,000 µm; (C, cross section) 50 µm; (F, inset) 250 µm; (F, 3D) 100 µm. All data are representative of at least three independent experiments. Results are presented as mean ± SEM.](JEM_20161645_Fig2){#fig2}

c-Fos promoted retinal angiogenesis via the neuronal STAT3/VEGF pathway {#s06}
-----------------------------------------------------------------------

IL-1β and TNF increase the expression of VEGF ([@bib35]); c-Fos transcriptionally regulates VEGF production in peritoneal inflammation via IL-1β and TNF ([@bib9]). We found that increased levels of *Il6* ([Fig. 1 E](#fig1){ref-type="fig"}), a transcriptional target of c-Fos, activated STAT3 and increased expression of *Vegfa* isoforms *Vegf120* and *Vegf164* ([Fig. 3 A](#fig3){ref-type="fig"}), which likely contributed to the neovascularization in *Vldlr^−/−^* retinas. *Vegfa* expression was markedly increased in *Vldlr^−/−^* mice at P12 and P17, as well as in the P12 photoreceptor layer of *Vldlr^−/−^* retinas ([Fig. 3, B and C](#fig3){ref-type="fig"}). VEGFA was reduced by *AAV2*-*hRK*--*sh_c-fos* in *Vldlr^−/−^* retinas ([Fig. 3 D](#fig3){ref-type="fig"}), which was associated with activated (phosphorylated) STAT3 and increased IL-6. We also knocked down VEGFA expression in photoreceptors using AAV2-*hRK*-*sh_Vegfa*, which strongly suppressed neovascularization in *Vldlr^−/−^* retinas ([Fig. 3, E and F](#fig3){ref-type="fig"}), suggesting that VEGFA from photoreceptors directly caused neovascularization, consistent with previous studies ([@bib59]; [@bib27]). Therefore, it is likely that c-Fos promoted neovascularization in the photoreceptor layer via VEGFA signaling, which may be driven by IL-6/STAT3.

![**c-Fos promoted retinal angiogenesis via VEGFA signaling modulated by neuronal IL-6/STAT3.** (A) *Vegf120* and *Vegf164* but not *Vegf188* expression was increased in P12 *Vldlr^−/−^* retinas. *n* = 6. (B and C) *Vegfa* expression was markedly increased in *Vldlr^−/−^* whole retinas at P12 and P17 (B) as well as in the photoreceptor layer (PL) of P12 *Vldlr^−/−^* retinas (C). *n* = 6. (D) The protein levels of c-Fos, pSTAT3, total STAT3, IL-6, and VEGFA in P12 WT, *Vldlr^−/−^*, and *Vldlr^−/−^* treated with *AAV2*-*hRK*--*sh_c-fos* or *AAV2*-*hRK*--*sh_control* (sh_con). *n* = 4--6. WB, Western blot. (E and F) Representative P16 whole mount images stained with isolectin IB4 and quantification showed that knocking down VEGFA in *Vldlr^−/−^* retinas using AAV2-*hRK*-*sh_Vegfa* reduced total lesion number by 55% compared with *AAV2*-*hRK*-*sh_control*--treated *Vldlr^−/−^* retinas. (E) Bars: (whole-mount images) 1,000 µm; (inset) 250 µm; (3D) 100 µm. PL, photoreceptor layer. All data are representative of at least three independent experiments. \*, P \< 0.05; \*\*\*, P \< 0.001. Results are presented as mean ± SEM.](JEM_20161645_Fig3){#fig3}

TNFAIP3, a gene important in cytokine-mediated immune and inflammatory responses, is induced by TNF, another c-Fos target gene. We found that TNFAIP3 was induced at both mRNA and protein levels in *Vldlr^−/−^* retinas ([Fig. 4, A and B](#fig4){ref-type="fig"}), concomitant with increased *Tnf*. Interestingly, TNFAIP3 is reported to suppress SOCS3 expression to enhance STAT3 proliferative signals ([@bib16]). We found that *Vldlr^−/−^* retinas have less SOCS3 expression than WT ([@bib56]). These findings suggested that STAT3 could also be activated by increased *Tnf*/*Tnfaip3* signals that further led to reduced *Socs3* level in *Vldlr^−/−^* retinas. Here, we showed that overexpression of *Socs3* mainly in the photoreceptor layer reduced neovascularization in *Vldlr^−/−^* retinas ([Fig. 4, C--F](#fig4){ref-type="fig"}). These results suggested that SOCS3 is critical to neovascularization and that reduction of SOCS3 expression in *Vldlr^−/−^* versus WT retinas may be secondary to up-regulation of *Tnf*/*Tnfaip3* induced by *c-fos*. SOCS3 inhibits activation of STAT3 by binding to the kinase JAK and the IL-6 receptor ([@bib66]), which induces the expression of VEGF ([@bib65]). Consistently, we found that, in *Vldlr^−/−^* retinas, overexpression of *Socs3* suppressed the increased VEGFA level by ∼45% ([Fig. 4 G](#fig4){ref-type="fig"}).

![**c-Fos promoted retinal angiogenesis via TNF/TNFAIP3/SOCS3.** (A and B) *Tnfaip3* mRNA (A; *n* = 6) and protein levels (B; *n* = 4) were increased in the developing *Vldlr^−/−^* retinas compared with WT controls. (C) *Lenti-Socs3* was injected subretinally into *Vldlr^−/−^* eyes, and SOCS3 protein levels were confirmed by Western blotting (WB). *n* = 3. con, control; non-treat, nontreated. (D) The infection of *lenti-Socs3* in the photoreceptor layer (PL) was confirmed by anti-SOCS3 antibody staining (cyan). 3D reconstructed representative images show that SOCS3 was mainly expressed in the photoreceptor layer after subretinal injection. *n* = 4. The asterisk in the lenti-control image indicates nonspecific staining. (E and F) Overexpression of Socs3 using *lenti-Socs3* inhibited neovascularization, including the retinal areas, which may not be completely affected by *lenti-Socs3* (∼25% not transfected; white arrowhead). (E) The representative whole-mount images of *lenti-control*-- or *lenti-Socs3*--treated *Vldlr^−/−^* retinas stained with isolectin IB4 to label endothelial cells. 3D reconstruction images show neovascularization in the photoreceptor layer. *n* = 6. (F) Quantification shows a decrease in both total lesion number and total lesion size in *lenti-Socs3*--treated *Vldlr^−/−^* retinas compared with lenti-control--treated *Vldlr^−/−^* retinas. *n* = 6. (G) Increased protein level of VEGFA in *Vldlr^−/−^* retinas was suppressed by *lenti-Socs3* treatment. *n* = 3. Bars: (E, whole-mount images) 1,000 µm; (E, inset) 250 µm; (D and E, 3D) 100 µm. All data are representative of at least three independent experiments. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. Results are presented as mean ± SEM.](JEM_20161645_Fig4){#fig4}

To confirm that c-Fos activates the STAT3/VEGFA pathway via IL-6 and TNF/TNFAIP3/SOCS3 signals in retinal photoreceptors, we examined *Vldlr*-deficient 661W photoreceptor cells (treated with AAV2-hRK-shRNA targeting *Vldlr*). Knocking down *Vldlr* increased mRNA expression of *c-fos*, *Il6*, *Tnf*, *Tnfaip3*, and *Vegfa*, also decreasing *Socs3*. In *Vldlr^−/−^* retinas, *AAV2*-*hRK*--*sh_c-fos* treatment restored *Il6*, *Tnf*, *Tnfaip3*, *Vegfa*, and *Socs3* expression to normal levels ([Fig. 5, A--G](#fig5){ref-type="fig"}). Thus, c-Fos in photoreceptors promoted retinal neovascularization via the neuronal STAT3/VEGF pathway induced by IL-6 and TNF/TNFAIP3/SOCS3 signals ([Fig. 5 H](#fig5){ref-type="fig"}).

![***c-Fos*regulated *Vegfa* via TNF/TNFAIP3/SOCS3 in photoreceptor cells.** (A--G) The mRNA levels of *Vldlr*, *c-fos*, *Il6*, *Tnf*, *Tnfaip3*, *Socs3*, and *Vegfa* in 661W photoreceptor cells treated with *AAV2*-*hRK*-*sh_Vldlr* and/or *AAV2*-*hRK*--*sh_c-fos* or *AAV2*-*hRK*-*sh_Control* (sh_con). \*\*, P \< 0.01; \*\*\*, P \< 0.001. *n* = 6. (H) A schematic diagram illustrates pathological neovascularization (NV) in the normal avascular photoreceptor layer controlled by transcriptional factor c-FOS through both IL-6/STAT3/VEGFA and TNF/TNFAIP3/SOCS3/STAT3/VEGFA pathways. All data are representative of at least three independent experiments. Results are presented as mean ± SEM.](JEM_20161645_Fig5){#fig5}

As c-Fos and c-Jun proteins form the AP-1 complex ([@bib13]), we also assessed the expression of *c-jun*, the levels of which were comparable between WT and *Vldlr^−/−^* retinas (Fig. S4). In addition, mRNA expression of urokinase-type plasminogen activator (*uPA*) was markedly increased in *Vldlr^−/−^* retinas (Fig. S4 B), suggesting that it might be a potential factor underlying high levels of transcription factor *c-fos* expression.

We previously found that energy deficiency in photoreceptors, which is exacerbated in the dark because of increased energy demand of the dark current, also causes an increase in photoreceptor VEGF and increased neovascularization in *Vldlr^−/−^* mice ([@bib27]). *c-fos* mRNA expression increased ∼10-fold at P8 and 20-fold at P12 in dark-reared (vs. 12 h dark/light control) *Vldlr^−/−^* mice (Fig. S4 C), suggesting that *c-fos* expression may also be mediated by increased photoreceptor energy demands of dark rearing in *Vldlr^−/−^* mice.

Pharmacologic inhibition of c-Fos suppressed retinal neovascularization {#s07}
-----------------------------------------------------------------------

SR11302 is a retinoid that specifically inhibits AP-1 activity without activating the transcription of retinoic acid response element ([Fig. 6 A](#fig6){ref-type="fig"}; [@bib20]). AP-1 consists of a family of c-Jun/c-Fos dimers that include different Jun proteins (c-Jun, JunB, and JunD) and Fos proteins (c-Fos, FosB, FosL1, FosL2, and FosB2; [@bib5]). The efficiency of SR11302 on AP-1 inhibition in SR11302-treated retinas was confirmed with the reduction of c-Fos target gene expression (*Il6*, *Il1β*, and *Tnf*), without a change in *c-fos* expression itself ([Fig. 6 B](#fig6){ref-type="fig"}). SR11302 treatment reduced the total vascular lesion number and lesion size in *Vldlr^−/−^* mice in a dose-dependent manner. High-dose SR11302 from P5 to P15 in *Vldlr^−/−^* mice reduced the total vascular lesion number by 48% and decreased the lesion size by 40% ([Fig. 6, C--E](#fig6){ref-type="fig"}), without detectable signs of toxicity in mice, including no change in body weight (Fig. S5).

![**c-Fos inhibitor SR11302 prevented retinal neovascularization.** (A) Schematic diagram illustrating how c-Fos inhibitor SR11302 may block c-Fos binding to its target promoters to inhibit target gene expression. (B) The mRNA levels of *c-fos* and its target genes (*Il6*, *Il1β*, and *Tnf*) in SR11302 (SR)-treated and control (con) *Vldlr^−/−^* retinas confirmed the efficiency of the c-Fos inhibitor. *n* = 6. (C) SR11302 inhibited neovascularization. Representative whole-mount images of control or SR11302-treated *Vldlr^−/−^* retinas stained with isolectin IB4 to label endothelial cells. Enlarged images show reduced total lesion number and lesion size in the SR11302-treated retinas. 3D reconstruction images show neovascularization in the photoreceptor cell layer. Bars: (whole-mount images) 1000 µm; (inset) 250 µm; (3D) 100 µm. (D and E) Quantification shows reduced total lesion number and lesion size (pixels) in SR11302-treated retinas compared with controls in a dose-dependent manner. *n* = 22--29. All data are representative of at least three independent experiments. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. Results are presented as mean ± SEM.](JEM_20161645_Fig6){#fig6}

Discussion {#s08}
==========

Here, we identify photoreceptors as the source of inflammatory signals that regulate the disruption of avascular privilege and later the disruption of immune privilege in photoreceptors in *Vldlr^−/−^* mice. We show that increased *c-fos* and inflammatory signals in the *Vldlr^−/−^* photoreceptor layer were associated with neovascularization invading a normally avascular-privileged zone, followed later by macrophage migration into the photoreceptor/subretinal space. Reducing *c-fos* expression suppressed local photoreceptor-produced proinflammatory cytokines and prevented neovascularization. Thus, photoreceptor inflammatory signals initiated neovessel growth into the avascular zone. It is plausible that *c-fos* could promote and *c-fos* inhibitors could suppress neovascularization in many eye diseases. The theoretical advantage in suppressing c-Fos (or AP-1) to suppress downstream targets (which include VEGF) rather than suppressing VEGF directly is that many AMD patients do not respond to anti-VEGF treatment and that inflammation is also a target in pathological retinal angiogenesis in neovascular eye diseases.

Although retinal inflammation is clearly involved in AMD, the relevant cells and pathways have not been fully defined. In *Vldlr^−/−^* mice, increased leukostasis and elevated levels of proinflammatory factors, such as intercellular adhesion molecule 1, TNF, endothelial nitric oxide synthase, and cyclooxygenase 2, indicate the presence of inflammation ([@bib12]). We showed a direct role for photoreceptor c-Fos (or AP-1) in promoting pathological vasculature in the photoreceptor avascular-privileged zone through photoreceptor-derived inflammatory mediators. AP-1 positively regulates the expression of inflammatory mediators such as IL-6 and TNF in a variety of cells ([@bib32]). The AP-1 complex is prototypically a c-Fos and c-Jun protein dimer ([@bib13]). In contrast to c-Jun proteins, c-Fos subunits cannot form homodimers but require combination with other binding proteins. In *Vldlr^−/−^* retinas, we found increased expression of *c-fos* but not of *c-jun*, which is likely to enlarge the pool of c-Fos available for heterodimerization and increase the fraction of AP-1 complexes composed of c-Fos and c-Jun ([@bib9]). This may directly affect proinflammatory cytokines gene expression, as complexes of c-Fos and c-Jun bind more effectively to target DNA sequences than c-Jun homodimers ([@bib23]). However, inflammatory cytokines including IL-6, TNF, and IL-1β can induce a rapid and transient expression of mRNA encoding c-Fos ([@bib38]). In *Vldlr^−/−^* retinas, the positive feedback loop of *c-fos* and cytokine-mediated inflammatory signals induced neovascularization. To explore the importance of this feedback loop in neovascularization, we broke down the positive feedback loop through subretinal injection of lentivirus expressing SOCS3, which inhibited STAT3 activation in *Vldlr^−/−^* retinas. Overexpression of SOCS3 led to reduced cytokine production and a 50% reduction of neovascularization in *Vldlr^−/−^* retinas. These findings suggest that the feedback loop of *c-fos*/inflammatory cytokines plays a critical role in *Vldlr* deficiency--induced neovascularization. This is consistent with our previous study ([@bib56]) showing that induction of retinal *Socs3* expression with a synthetic inverse agonist of retinoic acid receptor--related orphan receptor α (RORα) inhibited subretinal neovascular lesions in *Vldlr^−/−^* retinas.

The complex of uPA and plasminogen activator inhibitor 1 is one of the VLDLR ligands. It can promote cell proliferation and migration by activating the extracellular signal--regulated kinase pathway ([@bib64]). The plasminogen and plasminogen activator system consists of serine proteases that regulate migratory and tissue-remodeling events, such as those observed in neovascular AMD ([@bib43]). uPA mRNA is expressed in both choroidal neovascularization membranes extracted from patients with neovascular AMD and in experimentally induced choroidal neovascularization in mice ([@bib46]; [@bib7]). Increases in uPA are reported in patients with neovascular AMD ([@bib57]). However, the role of uPA in neovascular AMD is largely unknown. Binding of uPA to its receptor uPAR induces the rapid but transient expression of *c-fos* in human ovarian cancer cells ([@bib18]). This signal generates protein tyrosine kinase activity feeding into a signal transduction pathway that activates nuclear transcription factors ([@bib18]). Our data suggest that increases in free uPA caused by *Vldlr* deficiency (Fig. S4 B) might potentially induce expression of high levels of *c-fos*.

Our previous study ([@bib27]) found that dark-reared *Vldlr^−/−^* mice develop 1.5-fold more vascular lesions than 12-h light and dark cycle--raised mice, suggesting that energy metabolism influences neovascular disease, as dark rearing increases the energy demand of the dark current in photoreceptors ([@bib4]). In this study, we found that *c-fos* mRNA expression increased \>10-fold in dark-reared (vs. 12 h dark/light control) *Vldlr^−/−^* mice (Fig. S4 C), which suggests that *c-fos* expression is also mediated by increased photoreceptor energy demands of dark rearing in *Vldlr^−/−^* mice. There is a strong correlation between mRNA levels of *c-fos* in the ONL (photoreceptors) and the genes coding for the phototransduction proteins related to diurnal changes ([@bib40]). In rat retinas, *c-fos* mRNA is transiently expressed in the inner nuclear layer and ganglion cell layer after the onset of the light period and expressed continuously in the ONL throughout the dark period under a light/dark (12/12 h) cycle ([@bib68]). This relationship suggests that *c-fos* may also play a role in the transcriptional regulation of the genes encoding these light/dark cycle proteins ([@bib41]).

Our previous study ([@bib27]) shows that activation of the free fatty acid receptor 1 (*Ffar1*) impairs glucose entry into photoreceptors resulting in a dual (lipid and glucose) fuel shortage in *Vldlr^−/−^* mice that have impaired lipid uptake. This energy shortage results in a reduction in the levels of the Krebs cycle intermediate α-ketoglutarate, which promotes stabilization of hypoxia-induced factor 1α and secretion of VEGF by starved *Vldlr^−/−^* photoreceptors, leading to neovascularization. However, the double knockout *Vldlr^−/−^*/*Ffar1^−/−^* did not completely suppress the lesions, indicating that there are other pathways involved in this process. This study showed that *c-fos*--driven inflammation signals might also be induced during this energy-deprived process to control photoreceptor VEGF secretion.

Anti-VEGF drugs are widely used clinically to control the proliferation of pathological blood vessels driven by high levels of VEGF. However, basal levels of VEGF are needed for neuron and normal vessel survival. Under such circumstances, blocking only excess but not all VEGF will be very helpful. Targeting c-Fos or SOCS3 may prevent photoreceptor cells from releasing excessive VEGF without affecting its basal level.

*c-fos^−/−^* mice were reported to have reduced brain size because of apoptosis at the ventricular zone ([@bib61]), and retina from *c-fos^−/−^* mice have 23% fewer rod photoreceptor cells with 25% lower rhodopsin content ([@bib30]), suggesting *c-fos* is required for protection against cell apoptosis and that complete suppression of *c-fos* may be detrimental. We suppressed increased c-Fos using *si_c-fos*, *AAV2*-*hRK*--*sh_c-fos*, and SR11302 to control neovascularization in *Vldlr^−/−^* photoreceptors. Based on [Fig. 3 D](#fig3){ref-type="fig"}, the protein level of c-Fos after *AAV2*-*hRK*--*sh_c-fos* treatment for 3 mo was little higher than but comparable with that in WT, suggesting that normalization of the large increase in c-Fos seen with pathological neovascularization rather than complete suppression would be of benefit.

In summary, this study demonstrated that photoreceptor inflammatory signals initiate the vision-threatening invasion of blood vessels into an avascular-privileged zone in the retina. Retinal photoreceptor transcription factor c-Fos controls local inflammatory signaling to mediate neovascularization. Targeting the transcription factor c-Fos might be a novel way to prevent vision loss secondary to pathological retinal angiogenesis and may have broad therapeutic value for other vascular disorders involving photoreceptor microenvironmental inflammation.

Materials and methods {#s09}
=====================

Animals {#s10}
-------

All animal studies were performed according to protocols approved by the Institutional Animal Care and Use Committee at the Boston Children's Hospital. Mice were housed under specific pathogen--free conditions. *Vldlr^+/−^* (heterozygous) mice from The Jackson Laboratory (stock no. 002529) were crossed to generate homozygous and WT littermates. SR11302 (cat. 2476; Tocris Bioscience) was dissolved in corn oil. *Vldlr^−/−^* pups were orally gavaged with SR11302 or vehicle control (corn oil) at two doses (low dose 0.5 mg/kg body weight and high dose 1 mg/kg body weight) daily from P5 to P15. P16 retinas were collected for PCR and neovascularization analysis.

Neovascularization analysis {#s11}
---------------------------

*Vldlr^−/−^* and WT retina whole mounts were stained with isolectin IB4 and imaged with a microscope (AxioObserver.Z1; ZEISS) with a monochrome digital camera (AxioCam MRm; ZEISS) focusing on the terminal end of lesions on the RPE layer (usually at P16), and individual images were merged to create one retinal image using the automated merge function (mosaiX; ZEISS) in the software (AxioVision 4.6.3.0; ZEISS). ImageJ (National Institutes of Health) was used for quantification of subretinal neovascularization lesion number and areas in *Vldlr^−/−^* retinas with designed plugins adapted from the method used to measure retinal neovascularization (SWIFT\_ MACTEL) in the oxygen-induced retinopathy model ([@bib52]; [@bib27]). In brief, SWIFT_MACTEL isolates the red channel from a lectin-stained retinal whole mount, divides the image into four quadrants, and removes background fluorescence to allow for the neovascularization structures to stand out clearly against the background fluorescence of normal vessels. Using a slide bar to either increase or decrease a particular quadrant's fluorescence threshold, the SWIFT_MACTEL user designates a threshold that marks neovascularization structures but not normal vessels in each quadrant. After setting the appropriate threshold, artifacts like cellular debris or hyperfluorescent retinal edges can be manually removed and excluded from quantification. Then, SWIFT_MACTEL analyzes all pixels in the image that lie above the chosen intensity threshold and that are part of an object that has a minimum size of 100 pixels. By setting this cut off in object size, small artifacts like vessel branch points are automatically removed. After measuring all four quadrants, SWIFT_MACTEL creates a composite from all four neovascularization quadrants and calculates the total neovascularization pixel number. The *n* number is the number of eyes quantified. Lesion numbers and areas were quantified with researchers masked to the identity of samples.

Confocal imaging and 3D reconstruction {#s12}
--------------------------------------

At P16, mice were anesthetized, and the eyes were enucleated and fixed in 4% paraformaldehyde followed by dissection and staining of the retinas with fluoresceinated isolectin IB4 (Invitrogen) to visualize subretinal neovascularization in whole-mounted retinas. 3D reconstructed images were taken with confocal microscopy (TCS SP2 AOBS; Leica Biosystems), and z stacks were 3D reconstructed using Volocity software (PerkinElmer).

FFA {#s13}
---

Mice were anesthetized and injected intraperitoneally with fluorescein AK-FLUOR (Akorn) at 5 µg/g body weight. Fluorescent fundus images with dilated pupils were taken with a retinal-imaging microscope (Micron IV; Phoenix Research Laboratories) at 5 and 8 min after fluorescein injection.

Expression array {#s14}
----------------

Illumina mouse gene microarray analysis of P14 WT and *Vldlr^−/−^* retinas was performed in biological triplicate (Mouse-WG6 expression BeadChip; Illumina). The chip contains 45,000 probe sets representing 34,000 genes. Microarray studies, from cDNA synthesis to raw data normalization, were performed by the Molecular Genetics Core Facility at Boston Children's Hospital. In brief, total RNA (1 µg each) was reverse transcribed, followed by a single in vitro transcription amplification to incorporate biotin-labeled nucleotide, and subsequent hybridization and staining with strepatavidin-Cy3 was performed according to the manufacturer's instructions. The chip was scanned with a BeadArray Reader (Illumina) to measure the signal intensity of the labeled target. Raw data were analyzed with microarray software (Bead Studio Gene Expression; version 3.4.0; Illumina) for quality control, background analysis, and normalization with the rank-invariant algorithm. Normalized data were further analyzed for comparative molecular and cellular pathway regulation using Ingenuity Pathway Analysis (P = 0.05 and Δ of 0.19; QIAGEN; [@bib8]). The microarray data are available in the NCBI Gene Expression Omnibus database under accession no. [GSE78831](GSE78831).

Retina layer sectioning {#s15}
-----------------------

Retina layer sectioning of fresh prepared retinas was performed according to the following steps (Fig. S2). In brief, a fresh retina was dissected, and eight evenly spaced cuts were made radially to flatten the retina before placement on a parafilm-wrapped slide. A drop of optimal cutting temperature (OCT) medium was placed on top of the retina, and then the parafilm-wrapped slide with the retina was flipped upside down, gently placed on the flat surface of a pretrimmed frozen block of OCT, and held for 1--2 min to adhere to the OCT block. The slide and parafilm were gently removed, and the flattened retina was transferred onto frozen OCT medium. OCT medium was applied to cover the flattened retina, and the frozen block with the retina was placed in a cryostat. Each horizontal retinal section was cut at 20-µm thickness, and each of ∼12 sections per retina was collected into a separate RNase-free tube for RNA extraction.

Preparation of AAV2-*hRK*--*sh_c-fos* vector and AAV2 {#s16}
-----------------------------------------------------

Four independent shRNAs against mouse c-fos were designed using a published algorithm ([@bib42]). The sequences of the mouse c-fos shRNAs are as follows. *sh_c-fos* no. 1: 5′-ACCTGGTGCTGGATTGTATCTA-3′; *sh_c-fos* no. 2: 5′-GGACCTTACCTGTTCGTGAAAC-3′; *sh_c-fos* no. 3: 5′-GGTAGTTAGTAGAGCATGTGAG-3′; *sh_Vegfa* no. 1: 5′-AACCTCACCAAAGCCAGCACAT-3′; *sh_Vegfa* no. 2: 5′-AGGACCTTGTGTGATCAGACCA-3′; *sh_Vldlr* no. 1: 5′-GGAAAGTTCAAGTGCAGAAGCG-3′; *sh_Vldlr* no. 2: 5′-GGAATGCCATATCAACGAATGC-3′; *sh_Vldlr* no. 3: 5′-GGGATCTGCAGTCAAATTTGTA-3′; and scramble shRNA control: 5′-GATTTAAGACAAGCGTATAACA-3′. The shRNAs were cloned into a CAGmiR30-GFP plasmid to test the knockdown efficiency in pup retinas and photoreceptor 661W cells. T. Li (National Eye Institute, Bethesda, MD) and C. Cepko (Harvard Medical School, Boston, MA) provided AAV constructs containing the *hRK* promoter. Recombinant AAV2 vectors were produced as previously described ([@bib21]; [@bib60]). In brief, AAV vector, rep/cap packaging plasmid, and adenoviral helper plasmid were mixed with polyethylenimine (Sigma-Aldrich) and transfected into HEK293T cells (catalog no. HCL4517; Thermo Fisher Scientific). 72 h after transfection, cells were harvested, and the cell pellet was resuspended in virus buffer, followed by three cycles of freeze thaw and homogenization (Dounce). Cell debris was pelleted at 5,000 *g* for 20 min, and the supernatant was run on an iodixanol gradient. Recovered AAV vectors were washed three times with PBS using Amicon 100K columns (EMD Millipore). Real-time PCR was used to determine genome titers of the recombinant AAV. This protocol also was used to prepare a control (AAV2-shControl). Viruses were diluted to various concentrations to test infection, and a concentration of ∼2 × 10^12^ genome copies/ml was used for the experiments.

Subretinal injection {#s17}
--------------------

Subretinal injection into P1 neonate eyes was performed as previously described ([@bib37]; [@bib63]) under a dissection microscope. P1 *Vldlr^−/−^* or WT pups were anesthetized on ice for several minutes. The eyelid was prepared with Betadine, followed by water and then 70% ethanol using cotton swabs. A blade was used to gently cut open the eyelid. The injection needle was inserted into the eyeball through the incision until slight resistance was felt. Approximately 0.5 µl of solution containing siRNA/siControl or AAV2/control (10^12^--10^13^ genome copies/ml) was introduced into the subretinal space using a pulled angled glass pipette controlled by a FemtoJet microinjector (Eppendorf). *si_c-fos* was a pool of three sequences of siRNA (cat. 4390771; Ambion), containing three siRNA sequences (siRNA nos. s66197, s66198, and s66199). The left eyes were uninjected for within-animal controls. Curved forceps were used to slowly close the eyelid. Mice were placed on a circulating water blanket for warmth. The retinas were collected at P12 for PCR assay and P16 for whole mount analysis.

Immunohistochemistry {#s18}
--------------------

Immunohistochemistry in retinas was performed as described previously ([@bib10]; [@bib55],[@bib56]). In brief, eyes were isolated from *Vldlr^−/−^* and littermate WT mice and fixed in 4% paraformaldehyde for 1 h. Dissected retinas or frozen sections were placed in cold methanol for 20 min, blocked, and permeabilized in PBS containing 5% bovine serum albumin and 0.1% Triton X-100 for 1 h. The following antibodies were used: isolectin IB~4~ (121413; Invitrogen), CX3CR1 (bs-1728R; Bioss), IBA1 (019-19741; Wako Pure Chemical Industries), DAPI (D3571; Invitrogen), and SOCS3 (2923; Cell Signaling Technology). For morphological studies, mouse eyes were enucleated and fixed in 4% paraformaldehyde in PBS, cryoprotected in 30% sucrose in PBS, embedded in OCT compound (Tissue-Tek), and snap frozen. 16 µm--thick sections were taken on a cryostat (Leica Biosystems) and stained with hematoxylin and eosin (Sigma-Aldrich) followed by standard protocol.

RNA isolation and quantitative RT-PCR {#s19}
-------------------------------------

Total RNA was extracted from mouse retinas using an RNeasy kit (QIAGEN) and reverse transcribed with SuperScript III reverse transcription (Thermo Fisher Scientific) to generate cDNA. Quantitative PCR was performed using a 7300 system (Applied Biosystems) with SYBR FAST qPCR kits (Kapa Biosystems) using *Rhodopsin*, *Pecam*, *Vldlr*, *CD68*, *CD11β*, *CD45*, *c-fos*, *Il6*, *Il1β*, *Tnf*, *mmp10*, *Socs3*, *uPA*, *c-jun*, *Vegf120*, *Vegf164*, and *Vegf188* primers. Primer sequences for RT-PCR were as follows. *c-fos*: 5′-AACAGATCCGAGCAGCTTCTA-3′ (forward) and 5′-TTTTGAGCTTCAACCGGCATC-3′ (reverse); *c-jun*: 5′-GTCCCCTGTCTGATTTGTAGGAA-3′ (forward) and 5′-CCACACCATCTTCTGGTGTACAGT-3′ (reverse); *Il1b*: 5′-GCCCATCCTCTGTGACTCATG-3′ (forward) and 5′-GGAGCCTGTAGTGCAGCTGTCT-3′ (reverse); *Il6*: 5′-TGGAGTCACAGAAGGAGTGGCTAAG-3′ (forward) and 5′-TCTGACCACAGTGAGGAATGTCCAC-3′ (reverse); *Pecam1*: 5′-GAGCCCAATCACGTTTCAGTTT-3′ (forward) and 5′-TCCTTCCTGCTTCTTGCTAGCT-3′ (reverse); *Rhodopsin*: 5′-TCATGGTCTTCGGAGGATTCAC-3′ (forward) and 5′-TCACCTCCAAGTGTGGCAAAG-3′ (reverse); *Socs3*: 5′-GTTGAGCGTCAAGACCCAGT-3′ (forward) and 5′-GGGTGGCAAAGAAAAGGAG-3′ (reverse); *Tnf*: 5′-TCCAGTAGAATCCGCTCTCCT (forward) and 5′-GCCACAAGCAGGAATGAGAAG-3′ (reverse); *Tnfaip3*: 5′-ACCATGCACCGATACACGC-3′ (forward) and 5′-AGCCACGAGCTTCCTGACT-3′ (reverse); *uPA*: 5′-GAAGTCCTCCCTCCTTTAAATGTG-3′ (forward) and 5′-TGGGAGTTGAATGAAGCAGTGT-3′ (reverse); *Vegf120*: 5′-AACGATGAAGCCCTGGAGTG-3′ (forward) and 5′-TGAGAGGTCTGGTTCCCGA-3′ (reverse); *Vegf164*: 5′-AACGATGAAGCCCTGGAGTG-3′ (forward) and 5′-GACAAACAAATGCTTTCTCCG-3′ (reverse); *Vegf188*: 5′-AACGATGAAGCCCTGGAGTG-3′ (forward) and 5′-AACAAGGCTCACAGTGAACG-3′ (reverse); *Vegfa*: 5′-GGAGATCCTTCGAGGAGCACTT-3′ (forward) and 5′-GGCGATTTAGCAGCAGATATAAGAA-3′ (reverse); and *Vldlr*: 5′-TCTCTTGCTCTTAGTGATGG-3′ (forward) and 5′-CTTACAACTGATATTGCTGGG-3′ (reverse).

Western blotting {#s20}
----------------

A standard Western blot protocol was used with minor modifications. In brief, radioimmunoprecipitation assay buffer (89900; Thermo Fisher Scientific) was used to lyse cells. Proteinase inhibitor cocktail (P8340; Sigma-Aldrich) was added. Proteins were separated by electrophoresis using 4--12% NuPAGE Novex bis-Tris gels (NP0321BOX; Invitrogen). Mouse β-actin (A1978; Sigma-Aldrich) antibody was used for control.

Preparation of lenti-*Socs3* vector and virus {#s21}
---------------------------------------------

Mouse *Socs3* cDNA was inserted into plentiCMV/TO (775-1) with CMV promoter using a Gateway LR clonase kit (Invitrogen) according to the manufacturer's instruction, and sequences were confirmed by sequencing at the Boston Children's Hospital Intellectual and Developmental Disabilities Research Center Molecular Genetics Core Facility. *Socs3*-carrying lentiviruses were produced as follows. In brief, *Lenti*-*Socs3* or lenti-control, REV, VSVG, and pMDL (gas-pol) packaging plasmids were mixed with polyethylenimine and transfected into HEK293T cells (cat. no. HCL4517; Thermo Fisher Scientific). 72 h after transfection, the cell medium was harvested, and cellular debris was removed by centrifugation at 1,500 rpm before filtration over a 0.22-µm low-protein binding filter. Then, the filtered medium was centrifuged using a SW28 rotor (37 ml) for 2 h at 19,500 rpm (50,000 *g*) at 4°C. The supernatant was removed, and 100 ml PBS was added to the pellet and transferred to a new tube after 5--10 min. The virus was aliquotted and stored at −80°C.

Electroretinography (ERG) {#s22}
-------------------------

Retinal function was assessed by ERG as previously described ([@bib69]) in 3-mo untreated WT mice and littermate *Vldlr^−/−^* mice treated with AAV-*hRK*-shRNA targeting *c-fos* or *Vegfa* or AAV-*hRK*--sh_control. In brief, dark-adapted, anesthetized (ketamine/xylazine) mouse pupils were dilated (Cyclomydril; Alcon), and their corneas were anesthetized (proparacaine). A Burian--Allen bipolar electrode designed for the mouse eye (Hansen Laboratories) was placed on the cornea, and the ground electrode was placed on a foot. The stimuli consisted of a series of green LED flashes of doubling intensity from ∼0.0064--2.05 cd.s.m^−2^ and then white xenon arc flashes from ∼8.2−1,050 cd.s.m^−2^. The equivalent light for the green and white stimuli was determined from the shift of the stimulus/response curves. ERG stimuli were delivered using a Colordome Ganzfeld stimulator (Diagnosys LLC). The saturating sensitivity of the rod photoresponse was estimated by fitting a model of the biochemical processes involved in the activation of phototransduction to the ERG a-waves ([@bib31]; [@bib45]; [@bib26]).

Photoreceptor (661W) cell culture {#s23}
---------------------------------

Cone photoreceptor cells ([@bib2]; [@bib58]) were cultured as monolayers at 37°C and 5% CO~2~ in a humidified atmosphere in DMEM with FBS 10% supplemented with 20 µg/500 ml hydrocortisone (H-2270; Sigma-Aldrich), 20 µg/500 ml progesterone (P-8783; Sigma-Aldrich), 0.016 g/500 ml putrescine (P-7505; Sigma-Aldrich), and 20 µl/500 ml β-mercaptoethanol (M-6250; Sigma-Aldrich). No mycoplasma contamination of the cells was detected. An equal number of 661W cells (3 × 10^5^) was plated in each well of 6-well dishes. Cells were treated with *AAV2*-*hRK*-*sh_control* or *AAV2*-*hRK*--*sh_Vldlr* for overnight. On day 2, the cell medium was changed and treated with *AAV2*-*hRK*-*sh_control* or *AAV2*-*hRK*--*sh_c-fos* for overnight. On day 3, the medium was changed with fresh culture medium. After 48 h, photoreceptors were collected to determine gene expression by real time PCR.

Statistics {#s24}
----------

Results are presented as mean ± SEM and were compared using two-tailed unpaired Student's *t* test. Statistical analyses were performed with Prism (v5.0; GraphPad Software). A p-value \<0.05 was considered to be statistically significant.

Online supplemental material {#s25}
----------------------------

Fig. S1 shows there was no macrophage recruitment in P12 *Vldlr^−/−^* retinas. Fig. S2 shows a diagram of retinal layer sectioning. Fig. S3 shows knocking down *c-fos* reduced neovascularization in *Vldlr^−/−^* retinas. Fig. S4 shows the mRNA expression of *c-Jun* and *uPA* in WT and *Vldlr^−/−^* mice and the mRNA expression of c-fos in dark-adapted *Vldlr^−/−^* retinas. Fig. S5 shows the body weight of mice treated with a high dose of SR11302 or control from P5 to P15. Table S1 is included as an Excel file and shows upstream regulator prediction of the microarray data.
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